News & Updates

Show Multimedia Only

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

05 Jan 2021

New drug applications approved by US FDA as of 16 - 31 December 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

05 Jan 2021

Darolutamide improves OS in nmCRPC

30 Dec 2020 by

Treatment with darolutamide significantly improved overall survival (OS) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a prespecified final analysis of the ARAMIS* study presented at ESMO Asia 2020.

Darolutamide improves OS in nmCRPC

30 Dec 2020

Sex drive in hypogonadal men better on nasal testosterone vs clomiphene

25 Dec 2020 by

For men with hypogonadism, switching from clomiphene citrate to nasal testosterone boosts sex drive and normalizes oestradiol levels without having any detrimental effects on semen parameters, as shown in a study.

Sex drive in hypogonadal men better on nasal testosterone vs clomiphene

25 Dec 2020

News & Updates

Showing Urology articles

Showing

Specialty:

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

Original New Drug Application Approvals by US FDA (16 - 31 December 2020)

Darolutamide improves OS in nmCRPC

Darolutamide improves OS in nmCRPC

Sex drive in hypogonadal men better on nasal testosterone vs clomiphene

Sex drive in hypogonadal men better on nasal testosterone vs clomiphene